Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

LY4052031

Antibody-drug conjugate · Cytotoxic, directed at nectin-4 · developed by ELI LILLY &

Phase 1 Most advanced trial

LLY Developer

What is LY4052031?

LY4052031 is an antibody-drug conjugate composed of a human monoclonal antibody against nectin-4 conjugated to LSN3889710, a topoisomerase 1 inhibitor. The antibody targets nectin-4 on tumor cells; upon internalization, the payload inhibits DNA topoisomerase I, causing cell cycle arrest and apoptosis. It is studied in multiple solid tumors including breast, lung, esophageal, pancreatic, ovarian, cervical, and head and neck cancers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Antibody-drug conjugate
Targets: nectin-4, DNA topoisomerase I (secondary target)
Mechanism: Cytotoxic, directed at nectin-4
Pathways: DNA replication inhibition, cell cycle arrest, apoptosis
Therapy area: Oncology
Developer: ELI LILLY & (LLY)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

Conditions studied

Advanced Solid TumorBladder CancerCervical CancerEsophageal CancerHead and Neck Squamous Cell CarcinomaMetastatic Solid TumorNon-small Cell Lung CancerOvarian CancerPancreatic CancerProstate CancerRecurrent Solid TumorRenal Pelvis CancerTriple Negative Breast CancerUrinary Bladder Neoplasm

Other drugs acting on NECTIN4

MK-3120 Phase 1/2 Sutantatug Envedotin Phase 3

More from ELI LILLY &

Abemaciclib FDA approved Baricitinib FDA approved Donanemab FDA approved Dulaglutide FDA approved Imlunestrant FDA approved Lebrikizumab FDA approved Mirikizumab FDA approved Orforglipron FDA approved Pirtobrutinib FDA approved Selpercatinib FDA approved Tirzepatide FDA approved Brenipatide Phase 3

Sources

NCI Thesaurus

Updated Oct 3, 2026. Something wrong or missing? Report it on the LLY page.

Follow LLY, the company behind LY4052031

See LLY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LLY catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z